

10/550499

TMH:dv 5585-71694-01 RCD/P038154US

Express Mail Label No. EV514206003US

Date of Deposit: September 20, 2005

JC20 Rec'd PCT/PTO 20 SEP 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Andrews *et al.*

Application No. _____

Filed: Herewith

Confirmation No. _____

For: MODULATION OF CELL PHENOTYPE BY
INHIBITORY RNA

Examiner: _____

Art Unit: _____

Attorney Reference No. 5585-71694-01

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are twelve English-language. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. It is believed that no fee is due to file this IDS. If the Commissioner determines that a fee is due, Deposit Account authority is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By _____

Tanya M. Harding, Ph.D.
Registration No. 42,630

JC20 Rec'd PCT/PTO 20 SEP 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	5585-71694-01
	Application Number	10/550499
	Filing Date	Herewith
	First Named Inventor	Andrews
	Art Unit	
	Examiner Name	

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		PCT	WO 00/22136	20-Apr-00	Howe
		PCT	WO 02/08388	31-Jan-02	Kruijer
		PCT	WO 02/16620	28-Feb-02	Andrews et al.
		PCT	WO 03/080816	02-Oct-03	Andrews et al.
		PCT	WO 03/012082	13-Feb-03	Andrews et al.

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Andrews, "From teratocarcinomas to embryonic stem cells," <i>Phil. Trans. R. Soc. Lond.</i> 357:405-417 (2002)
		Draper et al., "Surface antigens of human embryonic stem cells: changes upon differentiation in culture," <i>J. Anat.</i> 200:249-258 (2002)
		Matin et al., "Specific Knockdown of Oct4 and β 2-microglobulin Expression by RNA Interference in Human Embryonic Stem Cells and Embryonic Carcinoma Cells," <i>Stem Cells</i> 22:659-668 (2004)
		Meng et al., "RNA interference in three ES cell lines from different mouse strains," <i>Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica</i> 35(3):238-246 (2003) <i>English Abstract Only</i>
		Pan et al., "Stem cell pluripotency and transcription factor Oct4," <i>Cell Research</i> 12(5-6):321-329 (2002)
		Stewart, "Oct-4, Scene 1: the drama of mouse development," <i>Nature Genetics</i> 24: 328-330 (2000)
		Velkey and O'Shea, "Oct4 RNA Interference Induces Trophectoderm Differentiation in Mouse Embryonic Stem Cells," <i>Genesis</i> 37:18-24 (2003)

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	